Bristol Myers Squibb (CELG-RI) EPS (Weighted Average and Diluted) (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported EPS (Weighted Average and Diluted) of $1.31 for Q1 2026, up 9.17% year-over-year from $1.2 in Q1 2025, and up 147.17% quarter-over-quarter from $0.53 in Q4 2025.
Bristol Myers Squibb (CELG-RI) EPS (Weighted Average and Diluted) (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of EPS (Weighted Average and Diluted) data on file, last reported at $1.31 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $1.31, up 9.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.56 (up 33.33% YoY), and the FY2025 annual result was $3.46, up 178.46% from the prior year.
- EPS (Weighted Average and Diluted) climbed to $1.31 in Q1 2026 per CELG-RI's latest filing, from $0.53 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.31 in Q1 2026 and troughed at -$5.89 in Q1 2024.
- A 5-year average of $0.42 and a median of $0.83 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) sank 650.47% in 2024, then surged 1225.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.95 in 2022, then decreased by 8.42% to $0.87 in 2023, then tumbled by 95.4% to $0.04 in 2024, then surged by 1225.0% to $0.53 in 2025, then jumped by 147.17% to $1.31 in 2026.
- Business Quant data shows CELG-RI's EPS (Weighted Average and Diluted) at $1.31 in Q1 2026, $0.53 in Q4 2025, and $1.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.31 |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 1.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 |
| Dec 31, 2025 | 0.53 |
| Sep 30, 2025 | 1.08 |
| Jun 30, 2025 | 0.64 |
| Mar 31, 2025 | 1.20 |
| Dec 31, 2024 | 0.04 |
| Sep 30, 2024 | 0.60 |
| Jun 30, 2024 | 0.83 |
| Mar 31, 2024 | -5.89 |
| Dec 31, 2023 | 0.87 |
| Sep 30, 2023 | 0.93 |
| Jun 30, 2023 | 0.99 |
| Mar 31, 2023 | 1.07 |
| Dec 31, 2022 | 0.95 |
| Sep 30, 2022 | 0.75 |
| Jun 30, 2022 | 0.66 |
| Mar 31, 2022 | 0.59 |
| Dec 31, 2021 | 1.07 |
| Sep 30, 2021 | 0.69 |
| Jun 30, 2021 | 0.47 |